中华皮肤科杂志 ›› 2026, e20240377.doi: 10.35541/cjd.20240377
郭澜 晋红中
收稿日期:2024-07-16
修回日期:2025-08-10
发布日期:2026-03-11
通讯作者:
晋红中
E-mail:jinhongzhong@263.net
基金资助:Guo Lan, Jin Hongzhong
Received:2024-07-16
Revised:2025-08-10
Published:2026-03-11
Contact:
Jin Hongzhong
E-mail:jinhongzhong@263.net
Supported by:摘要: 【摘要】 机体可以通过氨基酸代谢调控免疫应答,在自身免疫性疾病的发病过程中发挥作用。银屑病是一种常见的慢性自身免疫性皮肤疾病,其发病机制涉及到树突细胞、T细胞等免疫细胞的调节失衡。越来越多的证据表明,银屑病中特定氨基酸的水平失调及代谢过程与其发病机制之间互相关联,其中研究相对较多的是色氨酸和精氨酸的代谢。色氨酸和精氨酸代谢通过调控免疫应答在银屑病发病中起到重要作用,亦可能提供新的治疗靶点。本综述分别对色氨酸和精氨酸的代谢过程及对免疫系统的调节作用进行总结,并阐述其在银屑病发病作用中的研究进展,旨在以新的视角理解银屑病的发病机制,有助于提供疾病干预的新思路。
郭澜 晋红中. 色氨酸和精氨酸代谢对免疫反应的调控机制及其在银屑病发病中的作用研究进展[J]. 中华皮肤科杂志, 2026,e20240377. doi:10.35541/cjd.20240377
Guo Lan, Jin Hongzhong. Tryptophan and arginine metabolism in immune regulation and their role in the pathogenesis of psoriasis[J]. Chinese Journal of Dermatology,2026,e20240377. doi:10.35541/cjd.20240377
| [1] | Grohmann U, Mondanelli G, Belladonna ML, et al. Amino⁃acid sensing and degrading pathways in immune regulation[J]. Cytokine Growth Factor Rev, 2017,35:37⁃45. DOI: 10.1016/j.cytogfr.2017.05.004. |
| [2] | Grohmann U, Bronte V. Control of immune response by amino acid metabolism[J]. Immunol Rev, 2010,236:243⁃264. DOI: 10. 1111/j.1600⁃065X.2010.00915.x. |
| [3] | Mondanelli G, Iacono A, Carvalho A, et al. Amino acid metabolism as drug target in autoimmune diseases[J]. Autoimmun Rev, 2019,18(4):334⁃348. DOI: 10.1016/j.autrev. 2019.02.004. |
| [4] | Correale J. Immunosuppressive amino⁃acid catabolizing enzymes in multiple sclerosis[J]. Front Immunol, 2020,11:600428. DOI: 10.3389/fimmu.2020.600428. |
| [5] | Murray PJ. Amino acid auxotrophy as a system of immunological control nodes[J]. Nat Immunol, 2016,17(2):132⁃139. DOI: 10. 1038/ni.3323. |
| [6] | Merlo L, Grabler S, DuHadaway JB, et al. Therapeutic antibody targeting of indoleamine⁃2,3⁃dioxygenase (IDO2) inhibits autoimmune arthritis[J]. Clin Immunol, 2017,179:8⁃16. DOI: 10. 1016/j.clim.2017.01.016. |
| [7] | Shellard EM, Rane SS, Eyre S, et al. Functional genomics and insights into the pathogenesis and treatment of psoriasis[J]. Biomolecules, 2024,14(5). DOI: 10.3390/biom14050548. |
| [8] | Xue C, Li G, Zheng Q, et al. Tryptophan metabolism in health and disease[J]. Cell Metab, 2023,35(8):1304⁃1326. DOI: 10. 1016/j.cmet.2023.06.004. |
| [9] | Fiore A, Murray PJ. Tryptophan and indole metabolism in immune regulation[J]. Curr Opin Immunol, 2021,70:7⁃14. DOI: 10.1016/j.coi.2020.12.001. |
| [10] | Badawy AA. Kynurenine Pathway of tryptophan metabolism: regulatory and functional aspects[J]. Int J Tryptophan Res, 2017,10:1178646917691938. DOI: 10.1177/1178646917691938. |
| [11] | Basson C, Serem JC, Hlophe YN, et al. The tryptophan⁃kynurenine pathway in immunomodulation and cancer metastasis[J]. Cancer Med, 2023,12(18):18691⁃18701. DOI: 10.1002/cam4.6484. |
| [12] | Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease[J]. Cell Host Microbe, 2018,23(6):716⁃724. DOI: 10.1016/j.chom.2018.05.003. |
| [13] | Eminel S, Jin N, Rostami M, et al. Dimethyl⁃ and monomethylfumarate regulate indoleamine 2,3⁃dioxygenase (IDO) activity in human immune cells[J]. Exp Dermatol, 2017,26(8):685⁃690. DOI: 10.1111/exd.13138. |
| [14] | Harden JL, Lewis SM, Lish SR, et al. The tryptophan metabolism enzyme L⁃kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases[J]. J Allergy Clin Immunol, 2016,137(6):1830⁃1840. DOI: 10.1016/j.jaci.2015.09.055. |
| [15] | Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health[J]. Science, 2017,357(6349):aaf9794. DOI: 10.1126/science.aaf9794. |
| [16] | Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down⁃regulate T cell receptor zeta⁃chain and induce a regulatory phenotype in naive T cells[J]. J Immunol, 2006,176(11):6752⁃6761. DOI: 10. 4049/jimmunol.176.11.6752. |
| [17] | Amobi A, Qian F, Lugade AA, et al. Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression[J]. Adv Exp Med Biol, 2017,1036:129⁃144. DOI: 10.1007/978⁃3⁃319⁃67577⁃0_9. |
| [18] | Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells[J]. J Immunol, 2010,185(6):3190⁃3198. DOI: 10.4049/jimmunol.0903670. |
| [19] | Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway[J]. Trends Pharmacol Sci, 2023,44(7):442⁃456. DOI: 10.1016/j.tips.2023.04.006. |
| [20] | Guo L, Jin H. Research progress of metabolomics in psoriasis[J]. Chin Med J (Engl), 2023,136(15):1805⁃1816. DOI: 10. 1097/CM9.0000000000002504. |
| [21] | Li SS, Liu Y, Li H, et al. Identification of psoriasis vulgaris biomarkers in human plasma by non⁃targeted metabolomics based on UPLC⁃Q⁃TOF/MS[J]. Eur Rev Med Pharmacol Sci, 2019,23(9):3940⁃3950. DOI: 10.26355/eurrev_201905_17823. |
| [22] | Chen C, Hou G, Zeng C, et al. Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis[J]. Theranostics, 2021,11(2):754⁃767. DOI: 10.7150/thno.51154. |
| [23] | Miao H, Bai Y, Shen S, et al. Biological agent exerts therapeutic effects by reversing abnormalities in amino acid metabolic pathways in psoriasis[J]. Exp Dermatol, 2024,33(3):e15059. DOI: 10.1111/exd.15059. |
| [24] | Yu N, Peng C, Chen W, et al. Circulating metabolomic signature in generalized pustular psoriasis blunts monocyte hyperinflammation by triggering amino acid response[J]. Front Immunol, 2021,12:739514. DOI: 10.3389/fimmu.2021.739514. |
| [25] | Guo L, Wu C, Song B, et al. Exploration of circulating metabolic signature of erythrodermic psoriasis based on LC⁃MS metabolomics[J]. Exp Dermatol, 2024,33(5):e15103. DOI: 10.1111/exd.15103. |
| [26] | Llamas⁃Velasco M, Bonay P, José Concha⁃Garzón M, et al. Immune cells from patients with psoriasis are defective in inducing indoleamine 2,3⁃dioxygenase expression in response to inflammatory stimuli[J]. Br J Dermatol, 2017,176(3):695⁃704. DOI: 10.1111/bjd.14779. |
| [27] | Ito M, Ogawa K, Takeuchi K, et al. Gene expression of enzymes for tryptophan degradation pathway is upregulated in the skin lesions of patients with atopic dermatitis or psoriasis[J]. J Dermatol Sci, 2004,36(3):157⁃164. DOI: 10.1016/j.jdermsci. 2004.08.012. |
| [28] | Fujii K, Yamamoto Y, Mizutani Y, et al. Indoleamine 2,3⁃dioxygenase 2 deficiency exacerbates imiquimod⁃induced psoriasis⁃like skin inflammation[J]. Int J Mol Sci, 2020,21(15)DOI: 10.3390/ijms21155515. |
| [29] | Choudhary V, Ajebo E, Uaratanawong R, et al. Loss of indoleamine⁃2,3⁃dioxygenase⁃1 (IDO1) in knockout mice does not affect the development of skin lesions in the imiquimod⁃induced mouse model of psoriasis[J]. Int J Tryptophan Res, 2022,15:11786469221078191. DOI: 10.1177/11786469221078191. |
| [30] | Elizei SS, Pakyari M, Ghoreishi M, et al. IDO⁃expressing fibroblasts suppress the development of imiquimod⁃induced psoriasis⁃like dermatitis[J]. Cell Transplant, 2018,27(3):557⁃570. DOI: 10.1177/0963689718757482. |
| [31] | Wang M, Wang Y, Zhang M, et al. Kynureninase contributes to the pathogenesis of psoriasis through pro⁃inflammatory effect[J]. J Cell Physiol, 2022,237(1):1044⁃1056. DOI: 10.1002/jcp. 30587. |
| [32] | Roberson ED, Liu Y, Ryan C, et al. A subset of methylated CpG sites differentiate psoriatic from normal skin[J]. J Invest Dermatol, 2012,132(3 Pt 1):583⁃592. DOI: 10.1038/jid.2011.348. |
| [33] | Chiricozzi A, Guttman⁃Yassky E, Suárez⁃Fariñas M, et al. Integrative responses to IL⁃17 and TNF⁃α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis[J]. J Invest Dermatol, 2011,131(3):677⁃687. DOI: 10.1038/jid. 2010.340. |
| [34] | Clement CC, D'Alessandro A, Thangaswamy S, et al. 3⁃Hydroxy⁃L⁃kynurenamine is an immunomodulatory biogenic amine[J]. Nat Commun, 2021,12(1):4447. DOI: 10.1038/s41467⁃021⁃24785⁃3. |
| [35] | Salimi Elizei S, Poormasjedi⁃Meibod MS, Wang X, et al. Kynurenic acid downregulates IL⁃17/1L⁃23 axis in vitro[J]. Mol Cell Biochem, 2017,431(1⁃2):55⁃65. DOI: 10.1007/s11010⁃017⁃2975⁃3. |
| [36] | Qiao P, Zhang C, Yu J, et al. Quinolinic acid, a tryptophan metabolite of the skin microbiota, negatively regulates NLRP3 inflammasome through AhR in psoriasis[J]. J Invest Dermatol, 2022,142(8):2184⁃2193. DOI: 10.1016/j.jid.2022.01.010. |
| [37] | Spiera H, Lefkovits AM. Remission of psoriasis with low dietary tryptophan[J]. Lancet, 1967,2(7507):137⁃139. DOI: 10.1016/s0140⁃6736(67)92970⁃4. |
| [38] | Petrozzi JW, Rosenbloom J. Low⁃tryptophan diet in treatment of psoriasis[J]. JAMA, 1968,205(6):345⁃346. |
| [39] | Munder M. Arginase: an emerging key player in the mammalian immune system[J]. Br J Pharmacol, 2009,158(3):638⁃651. DOI: 10.1111/j.1476⁃5381.2009.00291.x. |
| [40] | Bogdan C. Nitric oxide synthase in innate and adaptive immunity: an update[J]. Trends Immunol, 2015,36(3):161⁃178. DOI: 10.1016/j.it.2015.01.003. |
| [41] | Mondanelli G, Bianchi R, Pallotta MT, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells[J]. Immunity, 2017,46(2):233⁃244. DOI: 10.1016/j.immuni.2017.01.005. |
| [42] | Pohla L, Ottas A, Kaldvee B, et al. Hyperproliferation is the main driver of metabolomic changes in psoriasis lesional skin[J]. Sci Rep, 2020,10(1):3081. DOI: 10.1038/s41598⁃020⁃59996⁃z. |
| [43] | Kamleh MA, Snowden SG, Grapov D, et al. LC⁃MS metabolomics of psoriasis patients reveals disease severity⁃dependent increases in circulating amino acids that are ameliorated by anti⁃TNFα treatment[J]. J Proteome Res, 2015,14(1):557⁃566. DOI: 10. 1021/pr500782g. |
| [44] | Hu X, Qi C, Feng F, et al. Combining network pharmacology, RNA⁃seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma ⁃ Smilax glabra Roxb herb pair for the treatment of psoriasis[J]. Phytomedicine, 2022,105:154384. DOI: 10.1016/j.phymed.2022.154384. |
| [45] | Wang H, Xie B, Lan L, et al. Metabolomics strategy of Pikang oral liquid in the treatment of psoriasis[J]. Biomed Chromatogr, 2023,37(6):e5598. DOI: 10.1002/bmc.5598. |
| [46] | Bruch⁃Gerharz D, Schnorr O, Suschek C, et al. Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation[J]. Am J Pathol, 2003,162(1):203⁃211. DOI: 10.1016/S0002⁃9440(10)63811⁃4. |
| [47] | Abeyakirthi S, Mowbray M, Bredenkamp N, et al. Arginase is overactive in psoriatic skin[J]. Br J Dermatol, 2010,163(1):193⁃196. DOI: 10.1111/j.1365⁃2133.2010.09766.x. |
| [48] | Grzywa TM, Sosnowska A, Matryba P, et al. Myeloid cell⁃derived arginase in cancer immune response[J]. Front Immunol, 2020,11:938. DOI: 10.3389/fimmu.2020.00938. |
| [49] | Cao LY, Chung JS, Teshima T, et al. Myeloid⁃derived suppressor cells in psoriasis are an expanded population exhibiting diverse T⁃cell⁃suppressor mechanisms[J]. J Invest Dermatol, 2016,136(9):1801⁃1810. DOI: 10.1016/j.jid.2016.02.816. |
| [50] | Hou Y, Zhang H, Zhu Y, et al. Targeting upregulation of the immunosuppressive activity of MDSCs with indirubin as a novel strategy to alleviate psoriasis[J]. Int Immunopharmacol, 2023,123:110710. DOI: 10.1016/j.intimp.2023.110710. |
| [51] | Köhler I, Bivik Eding C, Kasic NK, et al. NOS2⁃derived low levels of NO drive psoriasis pathogenesis[J]. Cell Death Dis, 2024,15(6):449. DOI: 10.1038/s41419⁃024⁃06842⁃z. |
| [52] | Xu H, Zhang X, Wang X, et al. Cellular spermine targets JAK signaling to restrain cytokine⁃mediated autoimmunity[J]. Immunity, 2024,57(8):1796⁃1811. DOI: 10.1016/j.immuni.2024. 05.025. |
| [53] | Wang MJ, Huang HJ, Xu YY, et al. Metabolic rewiring in keratinocytes by miR⁃31⁃5p identifies therapeutic intervention for psoriasis[J]. EMBO Mol Med, 2023,15(4):e15674. DOI: 10. 15252/emmm.202215674. |
| [1] | 中华医学会皮肤性病学分会银屑病专业委员会. 伴共病的银屑病管理共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(3): 193-207. |
| [2] | 王钧程 刘洁. [开放获取] 人工智能在银屑病临床诊疗与患者管理中的应用进展[J]. 中华皮肤科杂志, 2026, 0(3): 20240061-e20240061. |
| [3] | 周雨婷 宋清华 王文慧. [开放获取] 泛发性脓疱型银屑病的易感基因研究进展[J]. 中华皮肤科杂志, 2026, 0(3): 20240211-e20240211. |
| [4] | 杨远 邓丹琪. [开放获取] 关节病型银屑病早期诊断与治疗的研究进展[J]. 中华皮肤科杂志, 2026, 0(3): 20240376-e20240376. |
| [5] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤罕见病专业委员会. [开放获取] 佩索利单抗治疗炎症性皮肤病专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(2): 113-119. |
| [6] | 中国康复医学会皮肤病康复专业委员会 中国中西医结合学会皮肤性病专业委员会 . [开放获取] 老年银屑病诊疗与康复专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 0(1): 20250637-e20250637. |
| [7] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤病学分会. [开放获取] 肠道菌群移植治疗银屑病专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 0(1): 20250564-e20250564. |
| [8] | 袁瑾 曾晓丽 林粼 吴汶霖 黄悦 周昆丽 蔡良奇. 关节病型银屑病患者血清中成纤维细胞生长因子23的表达及其临床意义[J]. 中华皮肤科杂志, 2026, 59(1): 58-61. |
| [9] | 薛天萍 陆振中 王洪生. [开放获取] 银屑病发病机制与微生物菌群相关性研究进展[J]. 中华皮肤科杂志, 2026, 59(1): 89-92. |
| [10] | 中华医学会皮肤性病学分会银屑病学组. [开放获取] 阿普米司特治疗银屑病专家指导意见(2025版)[J]. 中华皮肤科杂志, 2025, 58(5): 416-424. |
| [11] | 李紫钰 鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383. |
| [12] | 中国医师协会皮肤科医师分会儿童学组 中华医学会皮肤性病学分会银屑病学组. 【开放获取】 儿童脓疱型银屑病诊疗中国专家共识(2025版)[J]. 中华皮肤科杂志, 2025, 58(4): 297-306. |
| [13] | 何春霞 晋红中. 【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314. |
| [14] | 李秀珍 徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响[J]. 中华皮肤科杂志, 2025, 58(3): 268-272. |
| [15] | 陈良宏 孙艳 王敬玉 吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268. |
|